Senior insider sale
ENLIVEN THERAPEUTICS, INC. — senior position signals high conviction
$1.89M
41.38K shares
What this filing means
ORBIMED CAPITAL LLC plans to sell 41.38K shares of ENLIVEN THERAPEUTICS, INC. valued at approximately $1.89M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 6/23/2026ACC: 0000947871-26-000648
Director10% Owner
Since Jul 2021
41.38K
Shares to sell
$1.89M
Approx. market value
31.13K
Acquired (3 months)
2
Planned
1 completed
Securities Acquired — Last 3 Months1
Merger
N/A
2/23/2023
31.13KTotal acquired31.13K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
2/23/2023 | Merger N/A | 31.13K | — |
| Total | 31.13K | ||
Planned & Completed Dispositions3
Completed
—Completed
Units to sell
10.24K
Market value
$461.1K
6/15/2026
Planned — Approximate Date
Nasdaq Stock MarketPlanned
Units to sell
1.75K
Market value
$80.3K
6/22/2026
Nasdaq Stock MarketPlanned
Units to sell
29.39K
Market value
$1.35M
6/22/2026
Total
Units
41.38K
Value
$1.89M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
6/15/2026 | 10.24K | $461.1K | — | Completed |
| Planned — Approximate Date | ||||
6/22/2026 | 1.75K | $80.3K | Nasdaq Stock Market | Planned |
6/22/2026 | 29.39K | $1.35M | Nasdaq Stock Market | Planned |
| Total | 41.38K | $1.89M | ||